Early intervention
Addressing viral presence in the upper airway during the first hours after exposure or symptom onset.
Respyx Health, Inc.
A non-vaccine early-intervention platform for upper respiratory hygiene
Respyx Health is developing a science-based approach to addressing viral presence in the upper airway during the earliest stages of exposure or infection.
Early intervention
Fine mist delivery
Proven oral chemistry
Built on oral solution chemistry with over 145 years of safe human use, Respyx Health is focused on timing, mucosal contact, and scalable deployment. The company is pursuing an investor- and partner-oriented path centered on licensing, strategic development, and practical routes to market.
The Problem
Upper respiratory infections remain among the most common health challenges worldwide. Many respiratory viruses begin and replicate in the mouth, throat, and nasopharynx, yet there are very few interventions designed specifically for this early stage.
Vaccines are essential tools for disease prevention, but they do not address the immediate period after exposure or the earliest stage of viral replication in the upper airway. Respyx Health is focused on this critical early window.
Our Approach
Respyx Health is developing a platform based on three simple elements that can support scalable deployment and strategic partnering.
Fine-mist delivery
Allowing droplets to contact oral and upper-airway mucosal surfaces in a practical and scalable way.
Proven oral chemistry
Using oral solution formulations with a long history of safe human use and documented antimicrobial properties.
Together, these elements create a practical, licensable approach designed for broad deployment rather than dependence on a single hardware configuration.
Scientific Foundation
A growing body of research suggests that certain oral solution formulations can reduce viral activity in the oral cavity and upper airway. Studies conducted by multiple academic groups, including research referenced by Cardiff University and published in peer-reviewed journals, have examined the ability of oral rinses to disrupt the lipid envelopes of respiratory viruses.
Respyx Health builds on these insights by focusing on delivery method and timing, rather than reinventing the underlying chemistry.
Intellectual Property
Respyx Health is based on patented methods relating to the use of oral solutions and applicators for addressing upper respiratory infections.
- US Patent 11,890,409
- US Patent 8,679,462
These patents provide a foundation for practical delivery approaches and potential partnerships with consumer health and medical device companies.
Partnership Opportunities
Respyx Health is exploring collaborations with:
- Consumer health companies
- Oral care manufacturers
- Medical device developers
- Research institutions
- Strategic investors focused on non-vaccine respiratory solutions
The company welcomes discussions with organizations interested in advancing safe and scalable approaches to upper respiratory hygiene and early-intervention product development.